News
CYCC
1.659
-1.27%
-0.021
Cyclacel Pharmaceuticals (CYCC) Upgraded to Strong Buy: Here's What You Should Know
NASDAQ · 1d ago
Weekly Report: what happened at CYCC last week (0715-0719)?
Weekly Report · 4d ago
Weekly Report: what happened at CYCC last week (0708-0712)?
Weekly Report · 07/15 10:44
Weekly Report: what happened at CYCC last week (0701-0705)?
Weekly Report · 07/08 10:45
Weekly Report: what happened at CYCC last week (0624-0628)?
Weekly Report · 07/01 10:46
Sector Update: Health Care Stocks Softer Late Afternoon
NASDAQ · 06/26 20:01
Cyclacel Pharma Shares Rise 11% After European Patent Allowance Notice for Plogosertib
Dow Jones · 06/26 14:42
CYCLACEL PHARMACEUTICALS: GOT NOTICE FROM EUROPEAN PATENT OFFICE OF INTENTION TO GRANT PATENT COVERING PLOGOSERTIB PHARMACEUTICAL COMPOSITIONS
Reuters · 06/26 13:20
Cyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical Compositions
Cyclacel Pharmaceuticals, Inc. Has received a notice from the European Patent Office of the intention to grant a patent. The European patent will provide exclusivity until August 2040. The Company is developing innovative medicines based on cancer cell biology. The patent includes claims to novel pharmaceutical compositions of plogosertib.
Barchart · 06/26 08:15
Cyclacel Pharmaceuticals Announces Key Corporate Decisions at 2024 Annual Meeting
TipRanks · 06/25 10:29
Weekly Report: what happened at CYCC last week (0617-0621)?
Weekly Report · 06/24 10:51
Weekly Report: what happened at CYCC last week (0610-0614)?
Weekly Report · 06/17 10:45
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Avidity Biosciences (NASDAQ:RNA) shares rose 24.5% to $36.0 during Wednesday's pre-market session. Molecular Partners shares moved upwards by 18.43% during the day. The company's market cap stands at $3.4 billion.
Benzinga · 06/12 12:06
Weekly Report: what happened at CYCC last week (0603-0607)?
Weekly Report · 06/10 10:46
12 Health Care Stocks Moving In Thursday's After-Market Session
Venus Concept (NASDAQ:VERO) stock rose 131.0% to $1.43 during Thursday's after-market session. Cyclacel Pharmaceuticals shares increased by 8.58% and Rallybio shares rose 4.69% during the same period. Losers Biomea Fusion and Bright Green stock fell 61.9% and 13.49% respectively.
Benzinga · 06/06 20:31
All You Need to Know About Cyclacel Pharmaceuticals (CYCC) Rating Upgrade to Buy
NASDAQ · 06/06 16:00
Cyclacel's Fadraciclib Reports Efficacy In Patient-Derived Colorectal Cancer Models At The 2024 ASCO Annual Meeting
- Novel CDK2/9 inhibitor fadraciclib induces anaphase catastrophe, a novel cancer-specific mechanism of action. The data were presented at a poster at the American Society of Clinical Oncology Annual Meeting. Cyclacel Pharmaceuticals is developing a novel treatment for metastatic colorectal cancer.
Benzinga · 06/04 12:27
CYCLACEL PHARMACEUTICALS: FADRACICLIB DEMONSTRATES EFFICACY IN PATIENT-DERIVED COLORECTAL CANCER MODELS AT 2024 ASCO ANNUAL MEETING
Reuters · 06/04 12:06
Analysts Are Bullish on Top Healthcare Stocks: Cytokinetics (CYTK), Perspective Therapeutics (CATX)
TipRanks · 06/04 11:50
Cyclacel Pharmaceuticals To Present Clinical Data At 2024 ASCO Annual Meeting Highlighting Oral Fadraciclib's Potential As A Precision Medicine For Cancer
Clinical, PK and PD data from novel CDK2/9 inhibitor fadraciclib monotherapy studies support ongoing proof of concept study in patients with solid tumors and lymphoma. Data presented at a poster at the American Society of Clinical Oncology Annual Meeting.
Benzinga · 06/03 12:38
More
Webull provides a variety of real-time CYCC stock news. You can receive the latest news about Cyclacel Pharma through multiple platforms. This information may help you make smarter investment decisions.
About CYCC
Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing cancer medicines based on cell cycle, transcriptional regulation and mitosis control biology. The transcriptional regulation program is evaluating fadraciclib, a Cyclin-dependent kinase 9 (CDK9) inhibitor, in solid tumors and hematological malignancies. The epigenetic/anti-mitotic program is evaluating plogosertib, in solid tumors and hematological malignancies. The Company's Plogosertib is a novel, small molecule, selective and potent Polo-like kinase 1 (PLK1) inhibitor, which has demonstrated potent and selective target inhibition (PLK1 IC50 approximately 3 nM) and efficacy in human tumor xenografts at non-toxic doses. Its translational biology program supports the development of plogosertib in solid tumor and hematological malignancy indications.